Switching from IV to subcutaneous infliximab maintenance therapy is associated with high treatment persistence and a stable ...
South Korean biosimilars developer Celltrion late yesterday announced new post-hoc analyses of its pivotal LIBERTY studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback